Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Genomic subtyping and therapeutic targeting of acute erythroleukemia|
|Citation:||Nature Genetics, 2019; 51(4):694-704|
|Ilaria Iacobucci … L. Bik To, Ian D. Lewis, Richard J. D’Andrea … Anna L. Brown, Hamish S. Scott, Christopher H. Hahn … Charles G. Mullighan|
|Abstract:||Acute erythroid leukemia (AEL) is a high-risk leukemia of poorly understood genetic basis, with controversy regarding diagnosis in the spectrum of myelodysplasia and myeloid leukemia. We compared genomic features of 159 childhood and adult AEL cases with non-AEL myeloid disorders and defined five age-related subgroups with distinct transcriptional profiles: adult, TP53 mutated; NPM1 mutated; KMT2A mutated/rearranged; adult, DDX41 mutated; and pediatric, NUP98 rearranged. Genomic features influenced outcome, with NPM1 mutations and HOXB9 overexpression being associated with a favorable prognosis and TP53, FLT3 or RB1 alterations associated with poor survival. Targetable signaling mutations were present in 45% of cases and included recurrent mutations of ALK and NTRK1, the latter of which drives erythroid leukemogenesis sensitive to TRK inhibition. This genomic landscape of AEL provides the framework for accurate diagnosis and risk stratification of this disease, and the rationale for testing targeted therapies in this high-risk leukemia.|
Leukemia, Erythroblastic, Acute
Tumor Suppressor Protein p53
Myeloid-Lymphoid Leukemia Protein
fms-Like Tyrosine Kinase 3
|Rights:||Copyright © 2019, Springer Nature|
|Appears in Collections:||Aurora harvest 8|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.